This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Skyworks (SWKS) & 3 Other Suppliers to Tap Uptick in iPhone Sales
by Radhika Pujara
Shares of Skyworks (SWKS) are skyrocketing post upbeat guidance and impressive Q1 performance driven by uptick in Apple's (AAPL) iPhone 12 sales. This positions other suppliers, including QRVO, JBL & SYNA, well to gain from the projected increase in iPhone 12 demand.
Skyworks' (SWKS) Q1 Earnings Top Estimates, Stock Up on Q2 View
by Zacks Equity Research
Skyworks' (SWKS) fiscal first-quarter results gain from rapid 5G deployment and strength in overall broad markets.
Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings
by Zacks Equity Research
Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.
Boston Scientific's (BSX) DBS System Gets FDA's Clearance
by Zacks Equity Research
The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.
Boston Scientific (BSX) Enhances Core Business With Buyout
by Zacks Equity Research
Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.
3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021
by Sriparna Ghosal
Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
Boston Scientific's (BSX) SCS Systems Receives FDA's Nod
by Zacks Equity Research
Boston Scientific's (BSX) WaveWriter Alpha portfolio of SCS Systems aims to widen the therapy options available for managing chronic pain.
Why Is Boston Scientific (BSX) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Stocks to Capitalize on Promising Medical Products Industry
by Trina Mukherjee
Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.
Boston Scientific (BSX) in Focus: Stock Moves 7% Higher
by Zacks Equity Research
Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Boston Scientific (BSX) Q3 Earnings Top, Margins Decline
by Zacks Equity Research
Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.
Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 48.00% and 5.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Q3 Earnings on Oct 28: BSX, CERN & More
by Urmimala Biswas
In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.
Boston Scientific (BSX) Q3 Earnings to Grow on Vital Procedures
by Zacks Equity Research
Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.
Analysts Estimate Boston Scientific (BSX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align's (ALGN) ClinCheck Suite Now Commercially Available
by Zacks Equity Research
Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.
Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View
by Zacks Equity Research
Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.
Baxter Supports Findings of Ongoing COVID-19 Nutrition Study
by Zacks Equity Research
The study, supported by Baxter (BAX) through an investigator-initiated grant, is the first analysis of longitudinal REE in critically ill, mechanically-ventilated COVID-19 patients.
Here's Why You Should Invest in AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
LHC Group (LHCG) and CHRISTUS Health Extend JV Partnership
by Zacks Equity Research
LHC Group (LHCG) and CHRISTUS Health expand their partnership to boost home health services and hospice care.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.
Allscripts Completes Sale of EPSi Business to Strata
by Zacks Equity Research
Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health